Ratings Moves: ING,...
Health Care: Drugs
ImmunoCellular Therapeutics Limited (IMUC: AMEX)
$2.58 0.03 | 1.18%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -14.50M | -5.72M | -6.15M | -2.63M |
| Operating Gains/Losses | 0.00 | 1.26K | -1.26K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | -623.54K | 0.00 | 0.00 | -24.95K |
| (Decrease) Increase In Payables | -401.09K | 962.88K | -54.54K | 92.65K |
| (Decrease) Increase In Other Current Liabilities | -79.29K | 168.36K | 126.26K | 95.02K |
| (Increase) Decrease In Other Working Capital | 0.00 | -105.58K | -3.26K | 0.00 |
| Other Non-Cash Items | 3.17M | -1.71M | 1.83M | 308.30K |
| Net Cash From Continuing Operations | -12.38M | -6.38M | -4.25M | -2.15M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -12.38M | -6.38M | -4.25M | -2.15M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -9.83K | -84.39K | -10.57K | -813.00 |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -9.83K | -84.39K | 1.07M | 1.92M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 31.95M | 7.85M | 26.50K | 474.56K |
| Repayment of Long-Term Debt | 0.00 | 53.02K | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | -100.00K | 8.15M | 0.00 |
| Net Cash From Financing Activities | 31.95M | 7.80M | 8.18M | 474.56K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 19.56M | 1.33M | 4.99M | 246.06K |
Portfolios with IMUC
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Setting Up...
Latest IMUC Headlines from TheStreet
- IMUC July Options Begin Trading 05.20.13 | 04:05 pm
- Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta 03.08.13 | 06:03 am
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- 3 Stocks Under $5 Making Big Moves 02.05.13 | 02:02 pm
- The Twitterverse's Biotech Stock Picks for 2013 01.02.13 | 08:01 am
- Biotech Stock Mailbag: Keryx, Amarin, ImmunoCellular 06.08.12 | 09:06 am
- 5 Stocks Under $10 Set to Soar 06.01.12 | 11:06 am
- 5 Stocks Under $10 Set to Soar 12.31.69 | 07:12 pm
Press Releases for IMUC
- ImmunoCellular Therapeutics To Present At Future Leaders Conference On April 5th - Business Wire 03.28.13 | 06:03 am
- ImmunoCellular Therapeutics To Present At ROTH Conference On March 18th - Business Wire 03.11.13 | 04:03 pm
- ImmunoCellular Therapeutics Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.05.13 | 04:03 pm
- ImmunoCellular Therapeutics Announces Issuance Of Key Patent For ICT-121 Cancer Vaccine - Business Wire 03.04.13 | 06:03 am
- ImmunoCellular Therapeutics To Report Financial Results For The Fourth Quarter And Full Year 2012 On March 5, 2013 - Business Wire 02.26.13 | 06:02 am
- ImmunoCellular Therapeutics To Present At BIO CEO & Investor Conference On February 11th - Business Wire 02.04.13 | 04:02 pm
- ImmunoCellular Therapeutics’ Investigational New Drug (IND) Application For ICT-140 Allowed By The FDA - Business Wire 01.29.13 | 06:01 am
- ImmunoCellular Therapeutics Provides Update On Corporate Milestones - Business Wire 01.07.13 | 06:01 am
- ImmunoCellular Therapeutics Appoints Gary S. Titus To Its Board Of Directors - Business Wire 01.02.13 | 06:01 am
- ImmunoCellular Therapeutics Appoints Andrew Gengos As Chief Executive Officer - Business Wire 12.03.12 | 04:12 pm
Partner Headlines for IMUC
- ImmunoCellular Update Adds Clarity And Further Validates Investment Thesis - Seeking Alpha 03.07.13 | 09:03 am
- ImmunoCellular Therapeutics: An Opportunity For Great Upside Potential - Seeking Alpha 11.21.12 | 08:11 am
- ImmunoCellular Therapeutics Announces Pricing of its Previously Announced Public Offering of Common Stock and Warrants - Benzinga 10.18.12 | 09:10 am
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- Reassessing & Continuing To Monitor Portfolios For Success - Seeking Alpha 07.30.12 | 09:07 am
- ImmunoCellular Provides Update on Phase II Clinical Trial of ICT-107 for Treatment of Glioblastoma - Benzinga 07.02.12 | 09:07 am
- MLV & Co Reiterates Buy, $4.50 PT on ImmunoCellular Therapeutics on Move to NYSE - Benzinga 05.25.12 | 12:05 pm
- Zacks Bull and Bear of the Day Highlights: ImmunoCellular, Willis Group Holdings, Encana, Exxon Mobil and Cenovus Energy - Press Releases - Zacks 02.21.12 | 09:02 am
- ImmunoCellular (IMUC) - Bull of the Day - Zacks 02.21.12 | 01:02 am
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
